Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jan 31;13(1):15-21.
doi: 10.21037/tcr-23-1477. Epub 2024 Jan 5.

CodeBreak 200: study limitations, and future directions

Malak Alharbi  1 , Muhammad Awidi  1 , Grace K Dy  1
Affiliations
Editorial

CodeBreak 200: study limitations, and future directions

Malak Alharbi et al. Transl Cancer Res. .
No abstract available

Keywords: CodeBreak 200 (CB200); KRAS G12C; Non-small cell lung cancer (NSCLC); brain metastases; sotorasib.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-23-1477/coif). G.K.D. reports that she received consulting fees from Amgen, Mirati, Regeneron, Eli Lilly, Janssen, Astra Zeneca, and Novartis. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Hunter JC, Manandhar A, Carrasco MA, et al. Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations. Mol Cancer Res 2015;13:1325-35. 10.1158/1541-7786.MCR-15-0203 - DOI - PubMed
    1. Ostrem JM, Peters U, Sos ML, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013;503:548-51. 10.1038/nature12796 - DOI - PMC - PubMed
    1. Dy GK, Govindan R, Velcheti V, et al. Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100. J Clin Oncol 2023;41:3311-7. 10.1200/JCO.22.02524 - DOI - PMC - PubMed
    1. de Langen AJ, Johnson ML, Mazieres J, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet 2023;401:733-46. 10.1016/S0140-6736(23)00221-0 - DOI - PubMed
    1. Choudhury NJ, Lavery JA, Brown S, et al. The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non-Small Cell Lung Cancer. Clin Cancer Res 2023;29:3418-28. 10.1158/1078-0432.CCR-23-0580 - DOI - PMC - PubMed